14th January 2014 Content supplied by:
DiaSorin Launch New Molecular Test for CMV
DiaSorin have a new molecular diagnostic test for the detection and quantification of Cytomegalovirus (CMV) in human fluid samples, available for use outside of the United States and Canada.
The new IAM CMV is the fifth test used on the LIAISON IAM after the first four assays already launched in 2012 and 2013 (IAM BKV, IAM VZV, IAM PARVO, IAM TOXO). The new molecular diagnostic test is of primary importance because it detects and quantifies clinically relevant subtypes of CMV in human plasma, urine and cerebrospinal fluid (CSF).
These features make the test a valuable tool for the diagnosis and monitoring of CMV infection in transplant recipients and other immunocompromised individuals as well as for the diagnosis of maternal and foetal CMV infection in early pregnancy and for monitoring CMV infection in affected babies. Cytomegalovirus (CMV) is a DNA virus belonging to the herpes virus family. CMV infection is common throughout the world with a seroprevalence of around 60% in the human population.
The LIAISON ® IAM analyser is a uniquely designed small footprint, bench top analyser which can connect to an IAM Control Unit (ICU) via a USB interface. The ICU runs uniquely designed, simple to use software in which a graphical user interface (GUI) guides the operator through a series of simple set up steps. From one to six instruments, can be connected to a single ICU, making LIAISON ® IAM perfect for laboratories who want to start with a small number of tests and add units as the workload or test portfolio grows.
Date Published: 14th January 2014